Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 5036 results found since Jan 2013.
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005
Source: Clinical Lymphoma and Myeloma - September 13, 2023 Category: Cancer & Oncology Authors: John M Burke Anthony Masaquel Rongrong Wang Farah Hossain Jia Li Summera Qiheng Zhou Carmen D Ng Matthew Matasar Source Type: research
Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study
CONCLUSIONS Satisfactory LDLT results were achieved in DSA- and CREG-alone-positive cases following desensitization therapy.PMID:37697637 | PMC:PMC10504854 | DOI:10.12659/AOT.941346
Source: Annals of Transplantation - September 12, 2023 Category: Transplant Surgery Authors: Kohei Ogawa Kei Tamura Katsunori Sakamoto Naotake Funamizu Masahiko Honjo Mikiya Shine Yusuke Nishi Tomoyuki Nagaoka Chihiro Ito Miku Iwata Mio Uraoka Yasutsugu Takada Source Type: research
Fragility fractures in lupus patients: Associated factors and comparison of four fracture risk assessment tools
CONCLUSIONS: OP is a common comorbidity in SLE patients, even in younger patients. FF appears to be more frequent in patients with hematologic involvement. The comparison of the four algorithms shows that DeFRA is the most accurate tool and should be applied to SLE patients.PMID:37698854 | DOI:10.1177/09612033231202701
Source: Lupus - September 12, 2023 Category: Rheumatology Authors: Fulvia Ceccarelli Giulio Olivieri Valeria Orefice Licia Picciariello Francesco Natalucci Fabrizio Conti Source Type: research
Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study
CONCLUSIONS Satisfactory LDLT results were achieved in DSA- and CREG-alone-positive cases following desensitization therapy.PMID:37697637 | PMC:PMC10504854 | DOI:10.12659/AOT.941346
Source: Annals of Transplantation - September 12, 2023 Category: Transplant Surgery Authors: Kohei Ogawa Kei Tamura Katsunori Sakamoto Naotake Funamizu Masahiko Honjo Mikiya Shine Yusuke Nishi Tomoyuki Nagaoka Chihiro Ito Miku Iwata Mio Uraoka Yasutsugu Takada Source Type: research
Association of giant cell hepatitis and autoimmune hemolytic anemia in infancy
Orv Hetil. 2023 Sep 10;164(36):1432-1436. doi: 10.1556/650.2023.32848. Print 2023 Sep 10.ABSTRACTGiant cell hepatitis associated with autoimmune hemolytic anemia (GCH-AIHA) is a rare disorder with unfavorable prognosis, affecting infants and young children. The mortality rate is high, complications of acute liver failure, sepsis, or liver transplantation can be responsible for fatal outcomes. An 18-month-old child who was diagnosed previously with autoimmune hemolytic anemia, developed acute hepatitis and acute liver failure concomitant to the relapse of the disease. GCH-AIHA is characterized by Coombs positive hemolytic a...
Source: Orvosi Hetilap - September 11, 2023 Category: General Medicine Authors: Katalin Csernus Alexandra T észás G ábor Ottóffy Antal Dezs őfi-Gottl Andr ás Tárnok Source Type: research
slan+ monocytes kill cancer cells coated in therapeutic antibody by trogoptosis
Cancer Immunol Res. 2023 Sep 11. doi: 10.1158/2326-6066.CIR-23-0239. Online ahead of print.ABSTRACTMonocytes positive for 6-Sulfo LacNAc (slan) are a major subset of non-classical CD14dimCD16+ monocytes in humans. We have shown that slan+ cells infiltrate lymphomas and elicit an antibody-dependent cellular cytotoxicity (ADCC) of neoplastic B cells mediated by the anti-CD20 therapeutic Rituximab. Herein, by performing blocking experiments and flow cytometry analyses, as well as confocal microscopy and live-cell imaging assays, we extended the findings to other humanized antibodies and deciphered the underlying effector mech...
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Giulia Finotti Enrica Pietronigro Camillo Balanzin Silvia Lonardi Gabriela Constantin Mark P Chao Cristina Tecchio William Vermi Marco A Cassatella Source Type: research
